✦ LIBER ✦

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

✍ Scribed by Y. Brandberg; S. Aamdal; L. Bastholt; M. Hernberg; U. Stierner; H. von der Maase; J. Hansson

Book ID: 116430945
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 419 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2011.11.019

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Two different durations of adjuvant ther

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

✍ Johan Hansson; Steinar Aamdal; Lars Bastholt; Yvonne Brandberg; Micaela Hernberg 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 283 KB

4LB Results of the Nordic randomised adj

4LB Results of the Nordic randomised adjuvant trial of intermediate-dose interferon alfa-2b in high-risk melanoma

✍ J. Hansson; S. Aamdal; L. Bastholt; M. Hernberg; B. Nilsson; U. Stierner; H. von 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 37 KB

Post-surgery adjuvant therapy with inter

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

✍ Alexander MM Eggermont; Stefan Suciu; Rona MacKie; Wlodzimierz Ruka; Alessandro 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 126 KB

A randomised phase II trial of 1 mo

A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients

✍ Lili Mao; Lu Si; Zhihong Chi; Chuanliang Cui; Xinan Sheng; Siming Li; Bixia Tang 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 305 KB

Immunomodulatory effects of high-dose an

Immunomodulatory effects of high-dose and low-dose interferon α2b in patients with high-risk resected melanoma : The E2690 laboratory corollary of Intergroup Adjuvant Trial E1690

✍ John M. Kirkwood; Thomas Richards; Hassane M. Zarour; Jeffrey Sosman; Marc Ernst 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Background: The clinical antitumor activity of recombinant interferon alpha2b (ifnalpha2b) has been well documented in patients with advanced and high-risk melanoma; however, its mechanism of action remains conjectural. trial e2690 evaluated the immunomodulatory effects of ifnalpha2b in vivo dur

Adjuvant therapy with pegylated interfer

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: An open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study

✍ Jean Jacques Grob; Thomas Jouary; Brigitte Dréno; Julien Asselineau; Ralf Gutzme 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 406 KB